Analytical Data
-
Gene name
DBI
- Application
-
Alternative Names
Diazepam-binding inhibitor (DBI) (Endozepine) (EP) (ACBP)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P31786
-
Expression Region
2-87aa
-
Molecular Weight
16.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of DBI (Dab1 Binding Protein) recombinant proteins has gained significant attention in the field of molecular biology and biochemistry due to their potential implications in various physiological processes and disease mechanisms. DBI, also known as Diazepam Binding Inhibitor, is a neuropeptide that plays a crucial role in regulating the activity of the GABA (gamma-aminobutyric acid) receptor, which is pivotal for neurotransmission and maintaining neuronal excitability. Alterations in DBI expression levels have been associated with several neurological disorders, including anxiety, depression, and epilepsy. The ability to produce recombinant DBI proteins allows researchers to investigate their structural and functional properties in detail, facilitating a better understanding of their role in cellular signaling pathways. Furthermore, recombinant DBI proteins present opportunities for pharmacological research aimed at developing novel therapeutic approaches to target related disorders. By using techniques such as molecular cloning, expression in heterologous systems, and purification protocols, scientists aim to generate functional DBI proteins for various applications, including drug discovery, functional assays, and structural analyses. Overall, the exploration of DBI recombinant proteins represents a vital step towards elucidating their biological functions and their potential as therapeutic targets in neuropsychiatric conditions.
